首页> 外文期刊>The Lancet >Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials.
【24h】

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials.

机译:强化控制血糖对糖尿病患者心血管结局和死亡的影响:一项随机对照试验的荟萃分析。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Whether intensive control of glucose reduces macrovascular events and all-cause mortality in individuals with type 2 diabetes mellitus is unclear. We undertook a meta-analysis of randomised controlled trials to determine whether intensive treatment is beneficial. METHODS: We selected five prospective randomised controlled trials of 33 040 participants to assess the effect of an intensive glucose-lowering regimen on death and cardiovascular outcomes compared with a standard regimen. We gathered information about events of non-fatal myocardial infarction, coronary heart disease (fatal and non-fatal myocardial infarction), stroke, and all-cause mortality, and did a random-effects meta-analysis to obtain summary effect estimates for the clinical outcomes with use of odds ratios calculated from the raw data of every trial. Statistical heterogeneity across trials was assessed with the chi(2) and I(2) statistics. FINDINGS: The five trials provided information on 1497 events of non-fatal myocardial infarction, 2318 of coronary heart disease, 1127 of stroke, and 2892 of all-cause mortality during about 163 000 person-years of follow-up. The mean haemoglobin A(1c) concentration (HbA(1c)) was 0.9% lower for participants given intensive treatment than for those given standard treatment. Intensive glycaemic control resulted in a 17% reduction in events of non-fatal myocardial infarction (odds ratio 0.83, 95% CI 0.75-0.93), and a 15% reduction in events of coronary heart disease (0.85, 0.77-0.93). Intensive glycaemic control had no significant effect on events of stroke (0.93, 0.81-1.06) or all-cause mortality (1.02, 0.87-1.19). INTERPRETATION: Overall, intensive compared with standard glycaemic control significantly reduces coronary events without an increased risk of death. However, the optimum mechanism, speed, and extent of HbA(1c) reduction might be different in differing populations. FUNDING: None.
机译:背景:强化血糖控制是否能减少2型糖尿病患者的大血管事件和全因死亡率。我们进行了一项随机对照试验的荟萃分析,以确定强化治疗是否有益。方法:我们选择了5个前瞻性随机对照试验,共33 040名参与者,与标准方案相比,评估了强化降糖方案对死亡和心血管结局的影响。我们收集了有关非致命性心肌梗塞,冠心病(致命和非致命性心肌梗塞),中风和全因死亡率的事件的信息,并进行了随机效应荟萃分析,以获取临床上的简要疗效估算使用根据每个试验的原始数据计算的比值比得出的结果。使用chi(2)和I(2)统计数据评估了整个试验的统计异质性。结果:这五项试验提供了关于约16.3万人年的非致命性心肌梗塞事件,2318例冠心病,1127例中风和2892例全因死亡率的信息。接受强化治疗的参与者的平均血红蛋白A(1c)浓度(HbA(1c))比接受标准治疗的参与者低0.9%。强化血糖控制可导致非致命性心肌梗塞事件减少17%(几率0.83,95%CI 0.75-0.93),而冠心病事件减少15%(0.85,0.77-0.93)。强化血糖控制对中风事件(0.93,0.81-1.06)或全因死亡率(1.02,0.87-1.19)没有显着影响。解释:与标准的血糖控制相比,总体而言,强化治疗可显着减少冠状动脉事件,而不会增加死亡风险。但是,HbA(1c)减少的最佳机制,速度和程度在不同人群中可能有所不同。资金:无。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号